Drug intelligence / Profile preview

KBD881

Development stage: Unknown
Lead developer: Chengdu Baiyu Jingelai Pharmaceutical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

KBD881 is a radiopharmaceutical candidate being developed by Chengdu Baiyu Jingelai Pharmaceutical and its subsidiary Kangbaida for the treatment of oncology. The drug is currently in Phase 1 clinical development. Its specific biological target and radioactive isotope remain undisclosed.

Beyond the preview

Go deeper on KBD881.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD881.

Explore the full profile